NO20090405L - Ikke-nukleoside revers transcriptase inhibitorer - Google Patents

Ikke-nukleoside revers transcriptase inhibitorer

Info

Publication number
NO20090405L
NO20090405L NO20090405A NO20090405A NO20090405L NO 20090405 L NO20090405 L NO 20090405L NO 20090405 A NO20090405 A NO 20090405A NO 20090405 A NO20090405 A NO 20090405A NO 20090405 L NO20090405 L NO 20090405L
Authority
NO
Norway
Prior art keywords
reverse transcriptase
transcriptase inhibitors
nucleoside reverse
compounds
hiv infection
Prior art date
Application number
NO20090405A
Other languages
English (en)
Inventor
Wylie Solang Palmer
Zachary Kevin Sweeney
Joshua Kennedy-Smith
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20090405L publication Critical patent/NO20090405L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Foreliggende oppfinnelse tilveiebringer forbindelser anvendelige for behandling av en HIV infeksjon eller forhindring av en HIV infeksjon eller behandling av AIDS eller ARC. Forbindelsene ifølge oppfinnelsen er med formel I hvor A er A1, A2, A3 eller A4 og R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 og X5 er som her definert. Også beskrevet i foreliggende oppfinnelse er metoder for behandling av en HIV infeksjon med forbindelser definert her og farmasøytiske preparater inneholdende nevnte forbindelser.
NO20090405A 2006-08-16 2009-01-28 Ikke-nukleoside revers transcriptase inhibitorer NO20090405L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83827206P 2006-08-16 2006-08-16
PCT/EP2007/058116 WO2008019968A1 (en) 2006-08-16 2007-08-06 Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
NO20090405L true NO20090405L (no) 2009-01-30

Family

ID=38663155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090405A NO20090405L (no) 2006-08-16 2009-01-28 Ikke-nukleoside revers transcriptase inhibitorer

Country Status (23)

Country Link
US (2) US7713974B2 (no)
EP (1) EP2057125B1 (no)
JP (1) JP5216768B2 (no)
KR (1) KR101401811B1 (no)
CN (1) CN101501002B (no)
AR (1) AR062366A1 (no)
AT (1) ATE503744T1 (no)
AU (1) AU2007286345B2 (no)
BR (1) BRPI0715193A2 (no)
CA (1) CA2658984C (no)
CL (1) CL2007002346A1 (no)
DE (1) DE602007013573D1 (no)
DK (1) DK2057125T3 (no)
ES (1) ES2360893T3 (no)
IL (1) IL196655A (no)
MX (1) MX2009001198A (no)
NO (1) NO20090405L (no)
PE (1) PE20080734A1 (no)
PL (1) PL2057125T3 (no)
PT (1) PT2057125E (no)
RU (1) RU2451676C2 (no)
TW (1) TWI417293B (no)
WO (1) WO2008019968A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
AU2008235549A1 (en) * 2007-04-09 2008-10-16 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US8877816B2 (en) * 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
MX2010006397A (es) 2007-12-21 2010-07-05 Hoffmann La Roche Compuestos heterociclicos antivirales.
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130072495A1 (en) * 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
WO2012078416A2 (en) * 2010-12-06 2012-06-14 Rfs Pharma, Llc Monophosphate prodrugs of dapd and analogs thereof
WO2012139495A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
MX350478B (es) 2011-04-26 2017-09-07 Procter & Gamble Miembros absorbentes voluminosos.
CN104394822B (zh) 2012-04-25 2018-07-27 宝洁公司 波纹形和开孔纤维网
CA2871673C (en) 2012-04-25 2018-04-17 The Procter & Gamble Company Apparatus and process for aperturing and stretching a web
WO2014091265A1 (en) 2012-12-11 2014-06-19 Aurigene Discovery Technologies Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
JP6321965B2 (ja) 2014-01-09 2018-05-09 富士フイルム株式会社 有機薄膜トランジスタ、有機半導体薄膜および有機半導体材料
CN106614663A (zh) * 2016-12-29 2017-05-10 新沂市中诺新材料科技有限公司 一种新型纳米级吲唑类农药合成方法
CN113511960A (zh) * 2021-08-20 2021-10-19 郑州华赞医药科技有限公司 一种1-氯-3-甲氧基-5-甲基苯的合成方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US3682932A (en) 1970-11-23 1972-08-08 Hoffmann La Roche 2-chloro-6-hydroxynicotinic acid
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4189718A (en) * 1978-03-02 1980-02-19 Carson Manufacturing Company, Inc. Electronic siren
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5489697A (en) 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
BR9509024A (pt) 1994-09-26 1997-09-30 Shionogi & Co Derivados de imidazol
WO1996025171A1 (en) 1995-02-16 1996-08-22 F.Hoffmann-La Roche Ag Inhibition of angiogenesis using interleukin-12
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
WO2000016625A1 (en) 1998-09-23 2000-03-30 University Of Kentucky Research Foundation Antiviral drug compositions containing lithium inorganic salts
FR2783826B1 (fr) 1998-09-29 2002-07-19 Rhodia Chimie Sa Procede de preparation de 4-hydroxyquinoleines et/ou formes tautomeres
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PL203116B1 (pl) 1999-05-04 2009-08-31 Schering Corp Piperazynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
CN1524527A (zh) 1999-05-04 2004-09-01 ���鹫˾ 用作ccr5拮抗剂的哌啶衍生物
AP1965A (en) 2000-05-26 2009-03-04 Pfizer Tropane derivatives useful in therapy.
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
US6620586B2 (en) 2001-02-20 2003-09-16 Applied Gene Technologies, Inc. Methods and compositions for analyzing nucleic acids
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
GB0108046D0 (en) 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds
CZ305099B6 (cs) 2001-04-10 2015-05-06 Pfizer Inc. Derivát pyrazolu, způsoby a meziprodukty pro výrobu, farmaceutická kompozice s jeho obsahem a jeho lékařské aplikace, zejména k léčení infekcí HIV
GB0113524D0 (en) 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
GB0127547D0 (en) 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
EP1546132A1 (en) 2002-09-26 2005-06-29 Pfizer Limited Pyrazole derivatives as reverse transcriptase inhibitors
GB0223234D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
AR042628A1 (es) 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
WO2005075484A2 (en) 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
CN1934092A (zh) * 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
ES2297727T3 (es) 2004-06-09 2008-05-01 F. Hoffmann-La Roche Ag Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos.
RU2394028C2 (ru) 2004-07-27 2010-07-10 Ф.Хоффманн-Ля Рош Аг Производные бензилтриазолона в качестве ненуклеозидных ингибиторов обратной транскриптазы
CA2577144C (en) 2004-09-30 2011-06-21 Boehringer Ingelheim International Gmbh Alkynyl compounds as non-nucleoside reverse transcriptase inhibitors
US20090264425A1 (en) 2004-12-22 2009-10-22 Pfizer Limited Chemical compounds
JP2008534456A (ja) 2005-03-24 2008-08-28 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式逆転写酵素インヒビターとしての１，２，４−トリアゾール−５−オン化合物
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
AU2006298853A1 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag NNRT inhibitors
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
WO2007045572A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
EP2001880A2 (en) * 2006-03-07 2008-12-17 Array Biopharma, Inc. Heterobicyclic pyrazole compounds and methods of use
EP2124944B1 (en) * 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
WO2010106333A1 (en) * 2009-03-19 2010-09-23 Medical Research Council Technology Compounds

Also Published As

Publication number Publication date
US20110059975A1 (en) 2011-03-10
MX2009001198A (es) 2009-02-11
JP2010500392A (ja) 2010-01-07
TWI417293B (zh) 2013-12-01
BRPI0715193A2 (pt) 2013-10-01
DE602007013573D1 (de) 2011-05-12
IL196655A (en) 2012-09-24
WO2008019968A1 (en) 2008-02-21
US7713974B2 (en) 2010-05-11
AR062366A1 (es) 2008-11-05
EP2057125B1 (en) 2011-03-30
DK2057125T3 (da) 2011-05-16
CN101501002B (zh) 2012-06-27
TW200817397A (en) 2008-04-16
AU2007286345A1 (en) 2008-02-21
RU2009109354A (ru) 2010-09-27
PE20080734A1 (es) 2008-06-14
US8063064B2 (en) 2011-11-22
KR20090040438A (ko) 2009-04-24
US20080045511A1 (en) 2008-02-21
EP2057125A1 (en) 2009-05-13
PT2057125E (pt) 2011-05-31
JP5216768B2 (ja) 2013-06-19
RU2451676C2 (ru) 2012-05-27
CL2007002346A1 (es) 2008-03-14
CN101501002A (zh) 2009-08-05
CA2658984A1 (en) 2008-02-21
ES2360893T3 (es) 2011-06-10
KR101401811B1 (ko) 2014-05-29
ATE503744T1 (de) 2011-04-15
PL2057125T3 (pl) 2011-09-30
IL196655A0 (en) 2009-11-18
AU2007286345B2 (en) 2012-03-08
CA2658984C (en) 2014-12-02

Similar Documents

Publication Publication Date Title
NO20090405L (no) Ikke-nukleoside revers transcriptase inhibitorer
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
NO20092636L (no) Ikke-nukleosid-reverstranskriptaseinhibitorer
MX2009009920A (es) Inhibidores no nucleosidos de transcriptasa inversa.
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
WO2007146230A3 (en) Non-nucleoside reverse transcriptase inhibitors
TW200738702A (en) HIV reverse transcriptase inhibitors
NO20090628L (no) Pyridizinon derivativater
WO2008054605A3 (en) Non-nucleoside reverse transcriptase inhibitors
NO20063958L (no) HIV integrase inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20045152L (no) Ikke-nukleosid-reverstranskriptaseinhibitorer
TN2010000212A1 (en) Inhibitors of human immunodeficiency virus replication
NO20073404L (no) Kaliumsalt av en HIV-integraseinhibitor
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20081217L (no) Nye benzotiazolonderivater
MX2010006397A (es) Compuestos heterociclicos antivirales.
TW200716571A (en) Heterocyclic reverse transcriptase inhibitors
TW200738700A (en) HIV integrase inhibitors
EP2033954A4 (en) COMPOUND 6- (4-OXOQUINOLIN-SUBSTITUTED BENZYL) AND USE THEREOF AS INHIBITOR OF HIV INTEGRASE
ATE517899T1 (de) Hiv-integrasehemmer
WO2007050510A3 (en) Hiv integrase inhibitors
TW200616933A (en) Benzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors
WO2007002458A3 (en) Non-nucleoside reverse transcriptase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application